Leukemia & Lymphoma最新文献

The prognostic implications of CDKN2A/2B deletion in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. CDKN2A/2B缺失对儿童急性淋巴细胞白血病预后的影响：一项系统综述和荟萃分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-25 DOI: 10.1080/10428194.2025.2521658

Sanjana Sarangarajan, Jagdish Prasad Meena, Aditya Kumar Gupta, Atul Batra, Jeeva Sankar, Sarita Kumari, Anita Chopra, Rachna Seth

{"title":"The prognostic implications of CDKN2A/2B deletion in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.","authors":"Sanjana Sarangarajan, Jagdish Prasad Meena, Aditya Kumar Gupta, Atul Batra, Jeeva Sankar, Sarita Kumari, Anita Chopra, Rachna Seth","doi":"10.1080/10428194.2025.2521658","DOIUrl":"https://doi.org/10.1080/10428194.2025.2521658","url":null,"abstract":"This review aimed to evaluate the impact of cyclin-dependent kinases 2 A/2B (CDKN2A/2B) deletion on survival in pediatric acute lymphoblastic leukemia (ALL). We pooled hazard ratios (HRs) and risk ratios (RRs) with 95% CIs, which were calculated using random-effects models. Individual patient data (IPD) were extracted from published survival curves of included studies, and combined HR was estimated. Fourteen studies (n = 2532 subjects) were included. CDKN2A/2B deletion was found to be associated with poor event/disease/relapse-free survivals at both study levels (HR 2.18; 95% CI: 1.46-3.27; I2 51%) and IPD level (HR 3.45; 95% CI 2.76-4.32 and p < 0.001); and poor overall survival at the IPD level (HR 3.22; 95% CI: 1.78-5.84 and p < 0.001). CDKN2A/2B deletion was also associated with a higher risk of poor prednisolone response (RR 1.38; 95% CI: 1.09-1.74; I2 7%) and relapse rates (RR 3.83; 95% CI: 2.76-5.3; I2 -0%). The meta-analysis highlights the negative impact of CDKN2A/2B deletions on disease outcome and treatment response. Hence, incorporating these alterations should improve risk stratification and risk-adapted treatment strategies for childhood ALL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under specific conditions, such as de novo cases: a case series of de novo CML-BC treated with ponatinib and no transplantation. 在特定情况下，波纳替尼可能使CML-BC不需要移植同种异体造血干细胞，例如新发病例：波纳替尼治疗的CML-BC新发病例系列，未移植。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-25 DOI: 10.1080/10428194.2025.2521646

Sukenao Koyabu, Takashi Onaka, Kazunori Imada

引用次数: 0

Use of doxorubicin is not associated with hemolytic complications in severely G6PD deficient patients with lymphoma. 严重G6PD缺陷淋巴瘤患者使用阿霉素与溶血并发症无关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-24 DOI: 10.1080/10428194.2025.2521654

Shruti Prem Sudha, Atef Shehata, Fatima Al-Ali, Nabil Abdelfattah, Taif Najeebi, Cigdem Ozturk, Aly Rashed, Manu Venkatesan, Rehab Helmy, Eman Aljufairi

{"title":"Use of doxorubicin is not associated with hemolytic complications in severely G6PD deficient patients with lymphoma.","authors":"Shruti Prem Sudha, Atef Shehata, Fatima Al-Ali, Nabil Abdelfattah, Taif Najeebi, Cigdem Ozturk, Aly Rashed, Manu Venkatesan, Rehab Helmy, Eman Aljufairi","doi":"10.1080/10428194.2025.2521654","DOIUrl":"https://doi.org/10.1080/10428194.2025.2521654","url":null,"abstract":"G6PD-deficiency is prevalent in the Middle East, and is linked to oxidative hemolysis with doxorubicin. Physicians substitute etoposide for doxorubicin in chemotherapy for G6PD-deficient lymphoma patients. We studied severely G6PD-deficient Hodgkin (HL) and diffuse large B cell lymphoma (DLBCL) patients. The primary outcome was the occurrence of hemolysis after doxorubicin, and secondary outcome was survival where etoposide was substituted for doxorubicin. Of 177 patients, 16% were severely G6PD-deficient. Eleven deficient HL patients had received ABVD, and seven deficient DLBCL patients had received R-CHOP, none had documented hemolysis. DLBCL patients who received R-CEOP had inferior survival compared to R-CHOP, while HL patients who received EBVD had comparable survival to ABVD. In the second part of the study, we prospectively monitored 39 severely G6PD-deficient lymphoma patients receiving doxorubicin, none had hemolysis. We conclude that doxorubicin is safe in severely G6PD-deficient patients. Substituting etoposide for doxorubicin in DLBCL was associated with decreased survival.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy. Pembrolizumab治疗复发或难治性霍奇金淋巴瘤：KEYNOTE-204的事后分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-23 DOI: 10.1080/10428194.2025.2502805

John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Yusuf, Patricia Marinello, Pier Luigi Zinzani

{"title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.","authors":"John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Yusuf, Patricia Marinello, Pier Luigi Zinzani","doi":"10.1080/10428194.2025.2502805","DOIUrl":"https://doi.org/10.1080/10428194.2025.2502805","url":null,"abstract":"This report focuses on a post hoc exploratory analysis of the phase 3 keynote-204 study comparing pembrolizumab and brentuximab vedotin by number of prior lines of therapy in participants with relapsed/refractory (r/r) classical hodgkin lymphoma (chl). of 304 participants randomly assigned (1: 1) to pembrolizumab or brentuximab vedotin, 55 received 1 prior therapy and 249 received ≥2. For 1 prior therapy, median progression-free survival (PFS) at primary analysis (including clinical imaging data after autologous stem cell transplant [auto-SCT]) was 16.4 months with pembrolizumab and 8.4 months with brentuximab vedotin; objective response rate (ORR) was 66.7% and 53.6%. For ≥2 prior therapies, median PFS at primary analysis was 12.6 months with pembrolizumab and 8.2 months with brentuximab vedotin; ORR was 65.3% and 54.4%. Pembrolizumab improved PFS and ORR versus brentuximab vedotin regardless of prior therapies. Data suggest pembrolizumab may be a promising second-line therapy for participants with R/R cHL ineligible for auto-SCT.Clinical trial information: ClinicalTrials.gov, NCT02684292.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fungal infections in hospitalized patients for chimeric antigen receptor (CAR) T-cell therapy: incidence and outcomes from a large inpatient database. 嵌合抗原受体（CAR） t细胞治疗住院患者的真菌感染：来自大型住院患者数据库的发病率和结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-22 DOI: 10.1080/10428194.2025.2523475

Anoosha Ponnapalli, Aditya Sharma, Aditi Sharma, Ayman O Soubani

引用次数: 0

Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis. 由于败血症导致的恶性血液病儿童死亡率和再次入院的危险因素。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-22 DOI: 10.1080/10428194.2025.2521650

Shlomit Barzilai-Birenboim, David M Zucker, Galia Avrahami, Sarah Elitzur, Salvador Fisher, Sarah Ganem, Gil Gilead, Shai Izraeli, Gili Kadmon, Eytan Kaplan, Aviva Krauss, Elhanan Nahum, Ron Rabinowicz, Jerry Stein, Osnat Tausky, Avichai Weissbach, Talya Wittmann Dayagi, Joanne Yacobovich, Asaf D Yanir

{"title":"Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis.","authors":"Shlomit Barzilai-Birenboim, David M Zucker, Galia Avrahami, Sarah Elitzur, Salvador Fisher, Sarah Ganem, Gil Gilead, Shai Izraeli, Gili Kadmon, Eytan Kaplan, Aviva Krauss, Elhanan Nahum, Ron Rabinowicz, Jerry Stein, Osnat Tausky, Avichai Weissbach, Talya Wittmann Dayagi, Joanne Yacobovich, Asaf D Yanir","doi":"10.1080/10428194.2025.2521650","DOIUrl":"10.1080/10428194.2025.2521650","url":null,"abstract":"Children with hematological malignancies, are often hospitalized in pediatric intensive care units (PICU) for sepsis with high mortality and re-admission rates. Risk factors for both are inconsistent. We reviewed data of 190 admissions of children with hematological malignancies to PICU for sepsis. Survival rate (SR) was 85%. Mortality risk factors were: non-complete remission (p < 0.01) and status post-stem cell transplantation (p = 0.02), and best predictors were inotropic drugs (p < 0.01), and Pediatric logistic organ dysfunction-2 (p < 0.01) scores. Patients with viremia had the lowest SR (50%, 0.001). One-quarter of the children were re-admitted due to sepsis, and risk factors were: High-risk (HR) hematological malignancy (p < 0.01) and lack of central venous line (CVL) removal (p < 0.01). Sepsis remains a major cause of death in children with hematological malignancies, and re-admissions are common. Our findings support the recommendation of removing CVL during sepsis and highlight those at the highest risk for sepsis to consider individualized anti-infectious prophylaxis.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY. 第一代和第二代酪氨酸激酶抑制剂治疗慢性粒细胞白血病慢性期患者的5年分子反应和总生存期：一项前瞻性观察性研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-22 DOI: 10.1080/10428194.2025.2495369

Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S DeGutis, Ali McBride, Lori Parsons, Monica Montelongo, Jorge E Cortes

{"title":"Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.","authors":"Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S DeGutis, Ali McBride, Lori Parsons, Monica Montelongo, Jorge E Cortes","doi":"10.1080/10428194.2025.2495369","DOIUrl":"10.1080/10428194.2025.2495369","url":null,"abstract":"SIMPLICITY (NCT01244750) was an observational study evaluating first-line (1 L) tyrosine kinase inhibitors (TKIs; dasatinib, nilotinib, imatinib) in patients with chronic myeloid leukemia in the chronic phase in routine clinical practice. At data cutoff (January 28, 2020), 810 prospective US patients were included/analyzed (dasatinib, 302; nilotinib, 264; imatinib, 244). Within 5 years, 95.4% of patients (dasatinib, 96.5%; nilotinib, 93.5%; imatinib, 95.9%) had major molecular response (BCR::ABL1 ≤ 0.1%), and 79.2% (dasatinib, 79.8%; nilotinib, 81.7%; imatinib, 75.9%) deep molecular response (MR4.5; BCR::ABL1 < 0.0032%) demonstrating major improvement during the study period. Of 734 patients followed for 5 years, 5-year overall survival rate was 89.8% (dasatinib, 92.9%; nilotinib, 88.6%; imatinib, 87.0%); similar to that in randomized studies. Patients who switched treatment had a poorer outcome regardless of TKI, indicating that non-kinase domain mutations may play a role. Despite missing data on outcomes in routine care, these results demonstrate excellent response and survival rates.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough. 在新诊断的急性髓系白血病患者中，尽管较低的药代动力学暴露，50 mg venetoclax与泊沙康唑与400 mg venetoclax的反应率比较：少就足够了。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-22 DOI: 10.1080/10428194.2025.2519921

Rudra Narayan Swain, Smita Pattanaik, Arihant Jain, Sarthak Wadhera, Charanpreet Singh, Alka Khadwal, Pankaj Malhotra, Gaurav Prakash

引用次数: 0

State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA). 美国急性髓性白血病（AML）的州际差异和时间趋势。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-20 DOI: 10.1080/10428194.2025.2515598

Rupayan Kundu, Kriti Soni, Rishabh Kundu, Sudipto Mukherjee

引用次数: 0

Optimal timing of allogeneic hematopoietic stem cell transplant in MDS. MDS患者异基因造血干细胞移植的最佳时机。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-19 DOI: 10.1080/10428194.2025.2514662

Kristin Rathje, Nicolaus Kröger

{"title":"Optimal timing of allogeneic hematopoietic stem cell transplant in MDS.","authors":"Kristin Rathje, Nicolaus Kröger","doi":"10.1080/10428194.2025.2514662","DOIUrl":"https://doi.org/10.1080/10428194.2025.2514662","url":null,"abstract":"Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, dysplasia, and a significant risk of progression to acute myeloid leukemia. Allogeneic hematopoietic stem cell transplant (HSCT) remains the only potentially curative therapy for MDS, particularly for higher-risk disease, but its success depends heavily on the timing of the procedure. This review explores the evolving evidence and decision models guiding the optimal timing of HSCT, balancing the risks of disease progression and transplant-related morbidity and mortality. Key considerations include advancements in disease-specific and transplant-specific risk stratification, such as the IPSS-M and transplant-specific scoring systems, which integrate clinical, cytogenetic, and molecular data to personalize timing decisions. Improvements in haploidentical HSCT and supportive care have expanded the feasibility and safety of HSCT for diverse patient populations, including the elderly. Prospective trials underscore the survival benefits of HSCT over non-transplant approaches for higher-risk MDS, while ongoing studies aim to address uncertainties in pretreatment, post-transplant maintenance therapy, and donor selection. By synthesizing these developments, this review provides practical insights into optimizing HSCT timing to improve outcomes for MDS patients.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0